| Dr Kye Patrick Evans, DO | |
|
325 Maine St, Lawrence, KS 66044-1360 | |
| (785) 505-6100 | |
| Not Available |
| Full Name | Dr Kye Patrick Evans |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 24 Years |
| Location | 325 Maine St, Lawrence, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750397618 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0529276 (Kansas) | Secondary |
| 207PE0005X | Emergency Medicine - Undersea And Hyperbaric Medicine | 0529276 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lawrence Memorial Hospital | Lawrence, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lawrence Physicians Llc | 1951623834 | 179 |
News Archive
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Soon in virtually every hospital it will be possible to identify the bacterial species responsible for an infection developing in a patient in a matter of just a few minutes.
The Pittcon Program Committee is pleased to announce this year's recipients of 13 prestigious awards honoring scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award will be presented in a scheduled symposium during Pittcon 2018, the world's leading conference and exposition for laboratory science, which will be held February 26-March 1, Orange County Convention Center, Orlando, Florida.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
Sigma-Aldrich has announced that it has granted Pfizer a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology. Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia.
› Verified 4 days ago
| Entity Name | Lawrence Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356469977 PECOS PAC ID: 9335057553 Enrollment ID: O20040306000096 |
News Archive
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Soon in virtually every hospital it will be possible to identify the bacterial species responsible for an infection developing in a patient in a matter of just a few minutes.
The Pittcon Program Committee is pleased to announce this year's recipients of 13 prestigious awards honoring scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award will be presented in a scheduled symposium during Pittcon 2018, the world's leading conference and exposition for laboratory science, which will be held February 26-March 1, Orange County Convention Center, Orlando, Florida.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
Sigma-Aldrich has announced that it has granted Pfizer a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology. Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia.
› Verified 4 days ago
| Entity Name | Lawrence Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346657590 PECOS PAC ID: 1951623834 Enrollment ID: O20141203002058 |
News Archive
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Soon in virtually every hospital it will be possible to identify the bacterial species responsible for an infection developing in a patient in a matter of just a few minutes.
The Pittcon Program Committee is pleased to announce this year's recipients of 13 prestigious awards honoring scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award will be presented in a scheduled symposium during Pittcon 2018, the world's leading conference and exposition for laboratory science, which will be held February 26-March 1, Orange County Convention Center, Orlando, Florida.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
Sigma-Aldrich has announced that it has granted Pfizer a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology. Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia.
› Verified 4 days ago
| Entity Name | Lawrence Emergency Medicine Associates P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013126630 PECOS PAC ID: 1052730025 Enrollment ID: O20200925000180 |
News Archive
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Soon in virtually every hospital it will be possible to identify the bacterial species responsible for an infection developing in a patient in a matter of just a few minutes.
The Pittcon Program Committee is pleased to announce this year's recipients of 13 prestigious awards honoring scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award will be presented in a scheduled symposium during Pittcon 2018, the world's leading conference and exposition for laboratory science, which will be held February 26-March 1, Orange County Convention Center, Orlando, Florida.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
Sigma-Aldrich has announced that it has granted Pfizer a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology. Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kye Patrick Evans, DO 325 Maine St, Lawrence, KS 66044-1360 Ph: (785) 505-6100 | Dr Kye Patrick Evans, DO 325 Maine St, Lawrence, KS 66044-1360 Ph: (785) 505-6100 |
News Archive
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Soon in virtually every hospital it will be possible to identify the bacterial species responsible for an infection developing in a patient in a matter of just a few minutes.
The Pittcon Program Committee is pleased to announce this year's recipients of 13 prestigious awards honoring scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award will be presented in a scheduled symposium during Pittcon 2018, the world's leading conference and exposition for laboratory science, which will be held February 26-March 1, Orange County Convention Center, Orlando, Florida.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
Sigma-Aldrich has announced that it has granted Pfizer a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology. Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia.
› Verified 4 days ago
Dr. Chad Ambrose Gustin, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 325 Maine St, Lawrence, KS 66044 Phone: 785-505-5000 | |
Wayne Tilson, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2904 Gill Ave, Lawrence, KS 66047 Phone: 785-841-9419 | |
Dr. Brian Hunt, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 325 Maine St, Lawrence, KS 66044 Phone: 785-505-6100 Fax: 785-505-2874 | |
James Herrin, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 325 Maine, Lawrence, KS 66044 Phone: 785-505-6162 | |
Dr. Scott A Robinson, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1112 W 6th St, Suite 109, Lawrence, KS 66044 Phone: 785-840-9292 Fax: 785-840-9272 | |
Dr. Mary Vernon, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4951 W 18th St, Lawrence, KS 66047 Phone: 785-841-6540 Fax: 785-841-3129 | |
Taylor Neff, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 325 Maine St, Lawrence, KS 66044 Phone: 785-505-5000 |